SPRY
ARS Pharmaceuticals, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ars-pharma.com
- Employees(FY) 24
- ISIN US82835W1080
Performance
+9.72%
1W
+10.8%
1M
+35.62%
3M
+39.58%
6M
+49.76%
YTD
+104.4%
1Y
Profile
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.
Technical Analysis of SPRY 2025-06-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2025-05-27 08:00
- 2025-03-22 19:18
Wall Street Week Ahead(Seekingalpha)
- 2025-03-21 00:40
Q4 2024 ARS Pharmaceuticals Inc Earnings Call(Yahoo Finance)
- 2025-03-21 00:16
- 2025-03-21 00:03
- 2025-03-20 15:03
- 2025-03-20 04:04
- 2025-03-20 03:31
- 2025-03-20 01:29
- 2025-03-20 01:28
- 2025-03-19 20:25
- 2025-03-19 19:00
- 2025-03-05 16:27
FDA approves ARS neffy 1mg for paediatric anaphylaxis(Yahoo Finance)
- 2025-03-03 03:35
- 2025-02-20 06:02
- 2025-02-17 19:00
- 2025-02-10 07:12
Oppenheimer Initiates ARS Pharmaceuticals at Outperform(MT Newswires)
- 2025-02-06 09:51
- 2025-02-05 08:00
- 2025-02-04 19:00
- 2025-01-31 10:02
3 US Growth Stocks With Significant Insider Ownership(Simply Wall St.)
- 2025-01-28 12:27
- 2025-01-21 08:00
- 2025-01-20 19:00
- 2025-01-13 16:15
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.(Investor's Business Daily)
- 2025-01-13 13:06
Exploring Three High Growth Tech Stocks In The United States(Simply Wall St.)
- 2025-01-13 08:00
- 2025-01-12 19:00
- 2025-01-07 06:43
ARS Pharma seeks approval for epinephrine spray in Canada and UK(Medical Device Network)
- 2025-01-06 19:15
Page 1 of 2
previousnext
Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.